Precision at Scale: Optimizing Cell-Free DNA Manufacturing for Next-Generation mRNA Vaccines and Therapeutics

Webinar
Written By Amy Fallon

Watch our on-demand Webinar

If you’re looking to improve mRNA manufacturing efficiency and overcome the limitations of traditional plasmid DNA templates, this on-demand webinar explores how synthetic, cell-free DNA can support greater quality, consistency, and scalability.

Presented by Dr. Ashish Dhir, Director of RNA at 4basebio, and hosted by Myles Skoda of Cell & Gene, the session shares comparative data on plasmid DNA and enzymatically produced, backbone-free linear DNA, highlighting key considerations for next-generation mRNA vaccines and therapeutics.

You’ll learn:

  • How synthetic DNA templates impact RNA yield, dsRNA levels, capping efficiency, and transcript integrity

  • The advantages of backbone-free linear DNA for long and self-amplifying RNA applications

  • How poly(A) tail homogeneity can be assessed using orthogonal analytical methodsRegulatory and CMC expectations when changing a core starting material

Amy Fallon
Next

Future-Proofing Your CMC Strategy: Managing Critical Starting Material Changes